Merck KGaA, Pfizer widen development of cancer immunology drug
November 04, 2015 at 08:31 AM EST
FRANKFURT, Nov 4 (Reuters) - Pfizer Inc and Germany's Merck KGaA started the second late-stage drug trial of its avelumab drug against lung cancer, targeting a slice of the growing but crowded cancer immunotherapy field.
